Samaritan's "Bull a Ton" Newsletter Announces Anticort Phase II HIV Data at First Blush is Promising - Promising Technology Available for Licensing and What Samaritan Might Look Like in the Future Business Wire
click here to return to Business Wire main menu
DonateNow





Samaritan's "Bull a Ton" Newsletter Announces Anticort Phase II HIV Data at First Blush is Promising - Promising Technology Available for Licensing and What Samaritan Might Look Like in the Future

Business Wire - August 08,2002

LAS VEGAS--(BUSINESS WIRE)--Aug. 8, 2002-- Samaritan Pharmaceuticals Inc. (OTCBB:SPHC) and Samaritan Research Labs, Georgetown University, announced in the first issue of its "Bull A Ton" newsletter that Anticort(R) for HIV, the most mature part of its pipeline, has promising, early, "first blush" data from its FDA Phase II clinical trial. http://www.samaritanpharmaceuticals.com/aug_2002_newsletter.pdf

Dr. Greeson, Chairman, CEO and President of Samaritan, stated, "We are currently conducting a detailed analysis of data to submit to peer review journals, present at medical conferences, possibly file for additional patent protections, and prepare for an extensive submission of data to the FDA. It is a lengthy process but we do have the wheels in motion. We expect the FDA to request at least a couple of Phase III human trials to confirm safety and the lack of side effects. So, in our opinion, the future for Anticort(R) looks pretty promising."

The newsletter, quoting John F Kennedy "We need men who can dream of things that never were," gives insight into what Samaritan believes it might look like in the future. It also updates its current pipeline, technology it believes is available for licensing and what Samaritan's value might look like in the future. To read newsletter and register to receive future newsletters electronically, go to www.samaritanpharmaceuticals.com.

About Samaritan Pharmaceuticals

Samaritan Pharmaceuticals is an emerging biopharmaceutical company that has collaborated with Georgetown University to provide its research arm. We are dedicated to saving lives, by developing "breakthrough discovery" for Alzheimer's, Cancer, Cholesterol Reduction, HIV and Parkinson's. Samaritan is busy building its patented pipeline, with one Phase II HIV drug candidate, an Alzheimer's and Breast Cancer Diagnostic, and nine drug candidates in various preclinical stages.

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 26, 2002. The company undertakes no duty to update forward-looking statements. Note: To receive future press releases automatically, or for more information, visit our Web site at www.samaritanpharmaceuticals.com.

CONTACT: Samaritan Pharmaceuticals Inc. Gene Boyle, 702/735-7001 Fax: 702/737-7016 GeneBoyle@aol.com

SOURCE: Samaritan Pharmaceuticals Inc.


020808
BW020804

Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .